For Research Use Only

anti-LAG3 recombinant VHH, FITC Plus



www.ptgcn.com

Catalog Number: FITC-lt

Catalog Number: FITC-lt **Basic Information**

Applications: FC, IF **Host:** Alpaca

Conjugate: FITC Plus

Type: Nanobody Class: Recombinant RRID: AB_3101919 **Molecular Weight:** 15.141 kDa

Description

FITC-lt targets LAG3 in FC and IF applications and shows reactivity with Human samples.

Affinity

Picomolar range, below the assay limit (biolayer interferometry)

Excitation/Emission Maxima Wavelengths 495 nm / 524 nm

Background


LAG-3, also known as CD223, is an immune checkpoint molecule that regulates both T-cell activation and homeostasis. LAG-3 is expressed on activated T cells, NK cells, regulatory T cells, and plasmacytoid dendritic cells. It is a CD4-related molecule that binds MHC class II. LAG-3 plays an important role in modulating T cell expansion and function, and blockade of LAG-3 with monoclonal antibodies can augment T cell function. (PMID: 15634887; 21086108; 28783703)

Storage


Store at -20°C; Shipped at ambient temperature.

Storage Buffer: 500 mM NaCl, 10 mM HEPES pH 7.0, 5 mM EDTA, 0.09% sodium azide


Selected Validation Data



1X10^6 HEK LAG3 transient transfected cells (red) and HEK parental cells were surface stained with 0.25 µg FITC Plus conjugated-LAG3 VHH (FITC-lt). Cells were not fixed.



Live HeLa cells transfected with human LAG3 were immunostained FITC Plus conjugated-LAG3 VHH (FITC-lt, 1:500, green). Cells were fixed and nuclei were stained with DAPI (cyan). Epifluorescence images were acquired with a 20x objective and post-processed. Note: Immunostaining with FITC-lt can also be performed after formaldehyde fixation of the cells.



Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) and CL405 CD3 (CL405-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) (red) or unstained (blue) LX10^6 untreated human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were not fixed. Lymphocytes were gated.